Assessment of compound AD-16´s possible inibitory action on neuroinflammation in animal model for Parkinson´s Disease

• Grant number: 23/05618-4
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: September 01, 2023
• Status: Discontinued
• Field of knowledge: Biological Sciences - Physiology - Physiology of Organs and Systems
• Principal Investigator: Luiz Roberto Giorgetti de Britto
• Grantee: Maria Eduarda Bianchetti Goulart
• Host Institution: Instituto de Ciências Biomédicas (ICB). Universidade de São Paulo (USP). São Paulo , SP, Brazil
• Associated scholarship(s): 24/22395-1 - BLOCKING NEUROINFLAMMATION: EVALUATION OF AD-16 MOLECULAR MECHANISMS IN A HUMAN MICROGLIAL CELL LINEAGE, BE.EP.IC

Abstract

Parkinson's Disease (PD) is a neurodegenerative condition that is characterized by the death of dopaminergic neurons of the substantia nigra pars compacta of the brain, and that includes motor as well as non-motor symptoms. An important aspect of this pathology is a marked neuroinflammation, which causes a neurotoxic deleterious cycle, which promotes the death of even more cells in the central nervous system. AD-16 is a recently discovered substance capable of reducing the expression of proinflammatory cytokines, such as IL-1², IL-12 and TNF-±, and of increasing the expression of antiinflammatory cytokines like IL-4, IL-10 in bothinduced and genetic models for the Alzheimer's Disease. We will use the toxin 6-hydroxydopamine for the induction of a model of PD in C57BL/6 male mice and immunohistochemistry techniques for proteins involved in PD pathology, such as tyrosine-hydroxylase and markers of microglial cells, and immunoblotting with labeling for some of the above cited cytokines. Thus, we seek the comprehension of AD-16 possible effects, after oral administration, on the contention of neuroinflammation also in PD and on the disease progression.

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

BIANCHETTI, MARIA E.; FERREIRA, ANA FLAVIA F.; BRITTO, LUIZ R. G.. Inhibition of neuroinflammation by GIBH-130 (AD-16) reduces neurodegeneration, motor deficits, and proinflammatory cytokines in a hemiparkinsonian model. FRONTIERS IN NEUROANATOMY, v. 18, p. 12-pg., 2024-12-16. (18/07366-4, 22/14846-8, 22/14820-9, 23/05618-4, 20/02109-3)